BiOptic Inc. is a biotechnology instrumentation company that develops innovative scientific products for research and clinical applications to improve the world around us.

The company was founded in 2004, with a vision of establishing high-quality, value-added and customer-driven OEM/ODM solutions by developing and manufacturing products utilizing Capillary Gel Electrophoresis (CGE) Technology for biotechnology laboratories all over the world. In 2009, BiOptic started to research and development of an innovative Capillary Gel Electrophoresis instrument utilizing disposable pen-shaped gel-cartridges. The first patented CGE-based Fragment Analyzer Qsep100 was launched in 2011 at the Lab Automation Conference in Palm Springs, CA.

With strong R & D, manufacturing and sales teams in China, Taiwan and the United States, BiOptic supports customers in over 50 Countries. Recently, BiOptic has expanded its portfolio of products by developing and introducing several CGE instruments: Qsep1, Qsep1-Lite, Qsep100, and Qsep400. In addition, we also provided the portable mini-PCR machine, Qampmini and newly launched innovative Direct RT-PCR reagent kits, a fast pathogen detection platform which could perfectly applied for the detection of various pathogens (such as the COVID-19). BiOptic provide a total solution from sample to result that customers, such as the epidemic prevention centers, only need to select specific gene loci to develop specific primers and directly apply to the BiOptic’s detection platform, where they can perform instant and rapid screening.

In past years, we have begun to cooperate with colleges to conduct on campus and industrial practice connection / education, hoping to cultivate more talents for biomedical related industries. At the same time, BiOptic also cooperates with academic and official health centers to actively participate in the prevention and control of epidemic diseases by using our products and technical expertise.